News

Asarina Pharma intends to carry out a directed share issue

Asarina Pharma AB (publ) (Nasdaq First North Growth Market: ASAP) (”Asarina Pharma” or the “Company”) today announces its intention to execute a directed share issue to institutional investors (the “Issue”).

Full PDF

First patient included in menstrual migraine study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announced the first patient has been included in its Phase IIa trial of Sepranolone in menstrual migraine (MM). The study will include 80-90 patients and is expected to be completed by the end of 2020.

Full PDF

Asarina Pharma AB (publ) Interim Report Q2 2019 released

Asarina Pharma CEO Peter Nordkild: “This has been a Quarter of important milestones: last patient in for our Phase IIb PMDD study, FDA approval of our IND for Sepranolone, Clinical Trial Approval for our Phase IIa Menstrual Migraine study and growing interest from future potential partners.”

Full PDF

Last Patient In for landmark PMDD study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announced the last patient was enrolled in the Phase IIb study for its first-in-class compound Sepranolone for premenstrual dysphoric disorder (PMDD). Top-line results are on track for late March 2020.

Full PDF

Sepranolone receives FDA IND approval in menstrual migraine

Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announces the FDA has approved the IND for its lead compound Sepranolone in menstrual migraine. It is an important confirmation of Sepranolone’s strong safety profile. 

Full PDF